Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]
Awaiting development
Reference number: GID-TA11538
Expected publication date: TBC
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-March 2025 when we will write to stakeholders about how they can get involved.